Поражение поджелудочной железы и воспалительные заболевания кишечника: случайное или закономерное сочетание? - Журнал Терапевтический архив №1 Поликлинические проблемы и организация медицинской помощи 2020
Поражение поджелудочной железы и воспалительные заболевания кишечника: случайное или закономерное сочетание?
Ахмедов В.А., Гаус О.В. Поражение поджелудочной железы и воспалительные заболевания кишечника: случайное или закономерное сочетание? Терапевтический архив. 2020; 92 (1): 76–81. DOI: 10.26442/00403660.2020.01.000463
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Патология поджелудочной железы при воспалительных заболеваниях кишечника (ВЗК) встречается чаще, чем в общей популяции, и включает широкий спектр проявлений от бессимптомных до тяжелых нарушений. Острый панкреатит, хронический панкреатит, аутоиммунный панкреатит, экзокринная недостаточность поджелудочной железы, повышение панкреатических ферментов и структурные аномалии протоков часто ассоциированы с ВЗК, при этом они могут быть как проявлением самого ВЗК, так и развиваться самостоятельно.
Ключевые слова: воспалительные заболевания кишечника, острый панкреатит, аутоиммунный панкреатит, хронический панкреатит, повышение панкреатических ферментов, структурные аномалии протоков поджелудочной железы, внекишечные проявления воспалительных заболеваний кишечника.
Keywords: inflammatory bowel disease, acute pancreatitis, autoimmune pancreatitis, chronic pancreatitis, increased pancreatic enzymes, structural anomalies of the pancreatic ducts, extraintestinal manifestations of inflammatory bowel disease.
Ключевые слова: воспалительные заболевания кишечника, острый панкреатит, аутоиммунный панкреатит, хронический панкреатит, повышение панкреатических ферментов, структурные аномалии протоков поджелудочной железы, внекишечные проявления воспалительных заболеваний кишечника.
________________________________________________
Keywords: inflammatory bowel disease, acute pancreatitis, autoimmune pancreatitis, chronic pancreatitis, increased pancreatic enzymes, structural anomalies of the pancreatic ducts, extraintestinal manifestations of inflammatory bowel disease.
Список литературы
1. Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G. Extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2015;21(8):1982-92. doi: 10.1097/MIB.0000000000000392
2. Ramos LR, Sachar DB, DiMaio CJ, Colombel JF, Torres J. Inflammatory bowel disease and pancreatitis: a review. J Crohns Colitis. 2016;10(1):95-104. doi: 10.1093/ecco-jcc/jjv153
3. Spanier BW, Dijkgraaf MG, Bruno MJ. Epidemiology, aetiology and outcome of acute and chronic pancreatitis: an update. Best Pract Res Clin Gastroenterol. 2008;22(1):45-63. doi: 10.1016/j.bpg.2007.10.007
4. Bermejo F, Lopez-Sanroman A, Taxonera C, Gisbert JP, Perez-Calle JL, Vera I, et al. Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine-induced pancreatitis. Aliment Pharmacol Ther. 2008;28(5):623-8. doi: 10.1111/j.1365-2036.2008.03746.x.
5. Weber P, Seibold F, Jenss H. Acute pancreatitis in Crohn's disease. J Clin Gastroenterol. 1993;17(4):286-91.
6. Rasmussen HH, Fonager K, Sorensen HT, Pedersen L, Dahlerup JF, Steffensen FH. Risk of acute pancreatitis in patients with chronic inflammatory bowel disease. A Danish 16-year nationwide follow-up study. Scand J Gastroenterol. 1999;34(2):199-201.
7. Chen YT, Su JS, Tseng CW, Chen CC, Lin CL, Kao CH. Inflammatory bowel disease on the risk of acute pancreatitis: A population-based cohort study. J Gastroenterol Hepatol. 2016;31(4):782-7. doi: 10.1111/ jgh.13171
8. Broide E, Dotan I, Weiss B, Wilschanski M, Yerushalmi B, Klar A, Levine A. Idiopathic pancreatitis preceding the diagnosis of inflammatory bowel disease is more frequent in pediatric patients. J Pediatr Gastroenterol Nutr. 2011;52(6):714-7. doi: 10.1097/MPG. 0b013e3182065cad
9. Moolsintong P, Loftus EV Jr, Chari ST, Egan LJ, Tremaine WJ, Sandborn WJ. Acute pancreatitis in patients with Crohn's disease: clinical features and outcomes. Inflamm Bowel Dis. 2005;11(12):1080-4. doi: 10.1097/01
10. Pajares JA, Hernandez L, Menchen P, Menchen L. Duodenopancreatic fistula complicating upper gastrointestinal Crohn's disease: successful treatment with infliximab. Am J Gastroenterol. 2009;104(7):1863-4. doi: 10.1038/ajg.2009.180
11. Goldin E, Libson E, Wengrower D, Antal S, Kovacs Z, Rachmilewitz D. Severe acute pancreatitis as the presenting symptom of primary sclerosing cholangitis: treatment by endoscopic insertion of a biliary stent. Int Surg. 1990;75(1):58-60.
12. Said K, Glaumann H, Bergquist A. Gallbladder disease in patients with primary sclerosing cholangitis. J Hepatol. 2008;48(4):598-605. doi: 10.1016/j.jhep.2007.11.019
13. Srinath AI, Gupta N, Husain SZ. Probing the association of pancreatitis in inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(2):465-75. doi: 10.1097/MIB.0000000000000611
14. Miehsler W, Reinisch W, Valic E, Osterode W, Tillinger W, Feichtenschlager T, et al. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut. 2004;53(4):542-8. doi: 10.1136/gut.2003.025411
15. Zhang FM, Xu CF, Shan GD, Chen HT, Xu GQ. Is gallstone disease associated with inflammatory bowel diseases? A meta-analysis. J Dig Dis. 2015;16(11):634-41. doi: 10.1111/1751-2980.12286
16. Fagagnini S, Heinrich H, Rossel JB, Biedermann L, Frei P, Zeitz J, et al. Risk factors for gallstones and kidney stones in a cohort of patients with inflammatory bowel diseases. PLoS One. 2017;12(10):e0185193. doi: 10.1371/journal.pone.0185193
17. Jeong YH, Kim KO, Lee HC, Sohn SH, Lee JW, Lee SH, et al. Gallstone prevalence and risk factors in patients with ulcerative colitis in Korean population. Medicine (Baltimore). 2017;96(31):e7653. doi: 10.1097/MD.0000000000007653
18. Faintuch J, Mott CB, Machado MC. Pancreatitis and pancreatic necrosis during sulfasalazine therapy. Int Surg. 1985;70(3):271-2.
19. Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions reevaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut. 2002;51(4):536-9. doi: 10.1136/gut.51.4.536
20. Russo L, Schneider G, Gardiner MH, Lanes S, Streck P, Rosen S. Role of pharmacoepidemiology studies in addressing pharmacovigilance questions: a case example of pancreatitis risk among ulcerative colitis patients using mesalazine. Eur J Clin Pharmacol. 2014;70(6):709-17. doi: 10.1007/s00228-014-1660-7
21. Isaacs KL, Murphy D. Pancreatitis after rectal administration of 5-aminosalicylic acid. J Clin Gastroenterol. 1990;12(2):198-9.
22. Stobaugh DJ, Deepak P. Effect of tumor necrosis factor-alpha inhibitors on drug-induced pancreatitis in inflammatory bowel disease. Ann Pharmacother. 2014;48(10):1282-7. doi: 10.1177/1060028014540869
23. Triantafillidis JK, Cheracakis P, Hereti IA, Argyros N, Karra E. Acute idiopathic pancreatitis complicating active Crohn's disease: favorable response to infliximab treatment. Am J Gastroenterol. 2000;95(11):3334-6.
24. Youssef I, Saeed N, El Abdallah M, Huevelhorst K, Zakharia K. Metronidazole-Induced Pancreatitis: Is There Underrecognition? A Case Report and SystematicReview of the Literature. Case Rep Gastrointest Med. 2019;2019:4840539. doi: 10.1155/2019/4840539
25. O'Halloran E, Hogan A, Mealy K. Metronidazole-induced pancreatitis. HPB Surg. 2010;2010:523468. doi: 10.1155/2010/523468
26. Tsesmeli NE, Giannoulis KE, Savopoulos CG, Vretou EE, Ekonomou IA, Giannoulis EK. Acute pancreatitis as a possible consequence of metronidazole during a relapse of ulcerative colitis. Eur J Gastroenterol Hepatol. 2007;19(9):805-6.
27. Sadr-Azodi O, Mattsson F, Bexlius TS, Lindblad M, Lagergren J, Ljung R. Association of oral glucocorticoid use with an increased risk of acute pancreatitis: a population-based nested case-control study. JAMA Int Med. 2013;173(6):444-9. doi: 10.1001/jamainternmed.2013.2737
28. Dong LH, Liu ZM, Wang SJ, Zhao SJ, Zhang D, Chen Y, Wang YS. Corticosteroid therapy for severe acute pancreatitis: a meta-analysis of randomized, controlled trials. Int J Clin Exp Pathol. 2015;8(7):7654-60.
29. Tenner S, Baillie J, DeWitt J, Vege SS, American College of G. American College of Gastroenterology guideline: management of acute pancreatitis. Am J Gastroenterol. 2013;108(9):1400-15;1416. doi: 10.1038/ajg.2013. 218
30. Nesvaderani M, Eslick GD, Cox MR. Acute pancreatitis: update on management. Med J Aust. 2015;202(8):420-3.
31. Охлобыстин А.В. Трудно ли диагностировать аутоиммунный панкреатит? Современные представления, подходы к лечению и исходы. Русский медицинский журнал. 2015;21:1281-6 [Okhlobystin AV. Is autoimmune pancreatitis difficult to diagnose? Modern views, treatment approaches and outcomes. Russian medical journal. 2015;21:1281-6 (In Russ.)].
32. Tsen A, Alishahi Y, Rosenkranz L. Autoimmune pancreatitis and inflammatory bowel disease: an updated review. J Clin Gastroenterol. 2017;51(3):208-14. doi: 10.1097/MCG.0000000000000737
33. Kamisawa T, Chari ST, Giday SA, Kim MH, Chung JB, Lee KT, et al. Clinical profile of autoimmune pancreatitis and its histological subtypes: an international multicenter survey. Pancreas. 2011;40(6):809-14. doi: 10.1097/MPA.0b013e3182258a15
34. Ueki T, Kawamoto K, Otsuka Y, Minoda R, Maruo T, Matsumura K, et al. Prevalence and clinico-pathological features of autoimmune pancreatitis in Japanese patients with inflammatory bowel disease. Pancreas. 2015;44(3):434-40. doi: 10.1097/MPA.000000000000026
35. Uchida K, Okazaki K. Clinical and pathophysiological aspects of type 1 autoimmune pancreatitis. J Gastroenterol. 2018;53(4):475-83. doi: 10.1007/s00535-018-1440-8
36. Lorenzo D, Maire F, Stefanescu C, Gornet JM, Seksik P, Serrero M, et al. Features of autoimmune pancreatitis associated with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2018;16(1):59-67. doi: 10.1016/j.cgh.2017.07.033
37. Ravi K, Chari ST, Vege SS, Sandborn WJ, Smyrk TC, Loftus EV, Jr. Inflammatory bowel disease in the setting of autoimmune pancreatitis. Inflamm Bowel Dis. 2009;15(9):1326-30. doi: 10.1002/ibd.20898
38. Smyk DS, Rigopoulou EI, Koutsoumpas AL, Kriese S, Burroughs AK, Bogdanos DP. Autoantibodies in autoimmune pancreatitis. Int J Rheumatol. 2012;2012:940831. doi: 10.1155/2012/940831
39. Ахмедов В.А., Гаус О.В. Современные взгляды на механизмы формирования и перспективы купирования болевого абдоминального синдрома у пациентов хроническим панкреатитом. Экспериментальная и клиническая гастроэнтерология. 2016;134(10):99-103 [Akhmedov VA, Gaus OV. Modern views on the mechanisms of formation and prospects for the relief of abdominal pain in patients with chronic pancreatitis. Experimental and clinical gastroenterology. 2016;134(10):99-103 (In Russ.)].
40. Хатьков И.Е., Маев И.В., Абдулхаков С.Р., Алексеенко С.А., Алиева Э.И., Алиханов Р.Б. и др. Российский консенсус по диагностике и лечению хронического панкреатита. Терапевтический архив. 2017;89(2):105-13 [Khatkov IE, Maev IV, Abdulkhakov SR, Alekseenko SA, Alieva EI, Alikhanov RB, et al. Russian consensus on the diagnosis and treatment of chronic pancreatitis. Therapeutic Archive. 2017;89(2):105-13 (In Russ.)]. doi: 10.17116/ terarkh20178 921 05-113
41. Ахмедов В.А., Гаус О.В. Поражение органов гепатобилиарной системы и поджелудочной железы при ожирении. Терапевтический архив. 2017;89(1):128-33 [Akhmedov VA, Gaus OV. Damage to the organs of the hepatobiliary system and pancreas in obesity. Therapeutic Archive. 2017;89(1):128-33 (In Russ.)]. doi: 10.17116/terarkh2017891128-133
42. Rana SS, Vilmann P. Endoscopic ultrasound features of chronic pancreatitis: A pictorial review. Endosc Ultrasound. 2015;4(1):10-4. doi: 10.4103/2303-9027.151314
43. Barthet M, Hastier P, Bernard JP, Bordes G, Frederick J, Allio S, et al. Chronic pancreatitis and inflammatory bowel disease: true or coincidental association? Am J Gastroenterol. 1999;94(8):2141-8.
44. Chen YL, Hsu CW, Cheng CC, Yiang GT, Lin CS, Lin CL, et al. Increased subsequent risk of inflammatory bowel disease association in patients with chronic pancreatitis: a nationwide population-based cohort study. Curr Med Res Opin. 2017;33(6):1077-82. doi: 10.1080/03007995.2017.1300143
45. Хатьков И.Е., Маев И.В., Бордин Д.С., Кучерявый Ю.А., Абдулхаков С.Р., Алексеенко С.А. и др. Российский консенсус по диагностике и лечению хронического панкреатита: заместительная ферментная терапия. Терапевтический архив. 2017;89(8):80-7 [Khatkov IE, Maev IV, Bordin DS, Kucheryavy YuA, Abdulkhakov SR, Alekseenko SA, et al. Russian consensus on the diagnosis and treatment of chronic pancreatitis: enzyme replacement therapy. Therapeutic Archive. 2017;89(8):80-7 (In Russ.)]. doi: 10.17116/terarkh 201789880-87
46. Maconi G, Dominici R, Molteni M, Ardizzone S, Bosani M, Ferrara E, et al. Prevalence of pancreatic in sufficiency in inflammatory bowel diseases. Assessment by fecal elastase-1. Dig Dis Sci. 2008;53(1):262-70. doi:10.1007/s10620-007-9852-y
47. Angelini G, Cavallini G, Bovo P, Brocco G, Castagnini A, Lavarini E, et al. Pancreatic function in chronic inflammatory bowel disease. Int J Pancreatol. 1988;3(2-3):185-93.
48. Heikius B, Niemela S, Lehtola J, Karttunen T, Lahde S. Pancreatic duct abnormalities and pancreatic function in patients with chronic inflammatory bowel disease. Scand J Gastroenterol. 1996;31(5):517-23.
49. Soubieres AA, Poullis A. Emerging role of novel bio- markers in the diagnosis of inflammatory bowel disease. World J Gastrointest Pharmacol Ther. 2016;7(1):41-50. doi: 10.4292/ wjgpt.v7.i1.41
50. Bogdanos DP, Rigopoulou EI, Smyk DS, Roggenbuck D, Reinhold D, Forbes A, et al. Diagnostic value, clinical utility and pathogenic significance of reactivity to the molecular targets of Crohn's disease specific-pancreatic autoantibodies. Autoimmun Rev. 2011;11(2):143-8. doi: 10.1016/j.autrev.2011.09.00
51. Bogdanos DP, Roggenbuck D, Reinhold D, Wex T, Pav lidis P, von Arnim U, et al. Pancreatic-specific autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with Crohn's disease. BMC Gastroenterol. 2012;12:102. doi: 10.1186/1471-230X-12-102
52. Pavlidis P, Romanidou O, Roggenbuck D, Mytilinaiou MG, Al-Sulttan F, Liaskos C, et al. Ileal inflammation may trigger the development of GP2-specific pancreatic autoantibodies in patients with Crohn's disease. Clin Dev Immunol. 2012;2012:640835. doi: 10.1155/2012/64083
53. Gross S, Bakker SF, van Bodegraven AA, van Hoogstraten IM, Gelderman KA, Bouma G, et al. Increased IgA glycoprotein-2 specific antibody titres in refractory celiac disease. J Gastrointestin Liver Dis. 2014;23(2):127-33. doi: 10.15403/jgld.2014.1121.232.sg1
54. Tornai T, Tornai D, Sipeki N, Tornai I, Alsulaimani R, Fechner K, Roggenbuck D, et al. Loss of tolerance to gut immunity protein, glycoprotein 2 (GP2) is associated with progressive disease course in primary sclerosing cholangitis. Sci Rep. 2018;8(1):399. doi: 10.1038/s41598-017-18622-1
55. Парфенов А.И., Быкова С.В., Сабельникова Е.А., Маев И.В., Баранов А.А., Бакулин И.Г. и др. Всероссийский консенсус по диагностике и лечению целиакии у детей и взрослых. Терапевтический архив. 2017;89(3):94-107 [Parfenov AI, Bykova SV, Sabelnikova EA, Mayev IV, Baranov AA, Bakulin IG, et al. All-Russian consensus on the diagnosis and treatment of celiac disease in children and adults. Therapeutic Archive. 2017;89(3):94-107 (In Russ.)]. doi: 10.17116/terarkh20 1789394-107
56. Fotios S Fousekis, Vasileios I Theopistos, Konstantinos H Katsanos, Dimitrios K Christodoulou. Pancreatic Involvement in Inflammatory Bowel Disease: A Review. J Clin Med Res. 2018;10(10):743-51. doi: 10.14740/jocmr3561w
57. Toda N, Akahane M, Kiryu S, Matsubara Y, Yamaji Y, Okamoto M, et al. Pancreas duct abnormalities in patients with ulcerative colitis: a magnetic resonance pancreatography study. Inflamm Bowel Dis. 2005;11(10):903-8. doi: 10.1097/01.mib.0000183419.17563.17
2. Ramos LR, Sachar DB, DiMaio CJ, Colombel JF, Torres J. Inflammatory bowel disease and pancreatitis: a review. J Crohns Colitis. 2016;10(1):95-104. doi: 10.1093/ecco-jcc/jjv153
3. Spanier BW, Dijkgraaf MG, Bruno MJ. Epidemiology, aetiology and outcome of acute and chronic pancreatitis: an update. Best Pract Res Clin Gastroenterol. 2008;22(1):45-63. doi: 10.1016/j.bpg.2007.10.007
4. Bermejo F, Lopez-Sanroman A, Taxonera C, Gisbert JP, Perez-Calle JL, Vera I, et al. Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine-induced pancreatitis. Aliment Pharmacol Ther. 2008;28(5):623-8. doi: 10.1111/j.1365-2036.2008.03746.x.
5. Weber P, Seibold F, Jenss H. Acute pancreatitis in Crohn's disease. J Clin Gastroenterol. 1993;17(4):286-91.
6. Rasmussen HH, Fonager K, Sorensen HT, Pedersen L, Dahlerup JF, Steffensen FH. Risk of acute pancreatitis in patients with chronic inflammatory bowel disease. A Danish 16-year nationwide follow-up study. Scand J Gastroenterol. 1999;34(2):199-201.
7. Chen YT, Su JS, Tseng CW, Chen CC, Lin CL, Kao CH. Inflammatory bowel disease on the risk of acute pancreatitis: A population-based cohort study. J Gastroenterol Hepatol. 2016;31(4):782-7. doi: 10.1111/ jgh.13171
8. Broide E, Dotan I, Weiss B, Wilschanski M, Yerushalmi B, Klar A, Levine A. Idiopathic pancreatitis preceding the diagnosis of inflammatory bowel disease is more frequent in pediatric patients. J Pediatr Gastroenterol Nutr. 2011;52(6):714-7. doi: 10.1097/MPG. 0b013e3182065cad
9. Moolsintong P, Loftus EV Jr, Chari ST, Egan LJ, Tremaine WJ, Sandborn WJ. Acute pancreatitis in patients with Crohn's disease: clinical features and outcomes. Inflamm Bowel Dis. 2005;11(12):1080-4. doi: 10.1097/01
10. Pajares JA, Hernandez L, Menchen P, Menchen L. Duodenopancreatic fistula complicating upper gastrointestinal Crohn's disease: successful treatment with infliximab. Am J Gastroenterol. 2009;104(7):1863-4. doi: 10.1038/ajg.2009.180
11. Goldin E, Libson E, Wengrower D, Antal S, Kovacs Z, Rachmilewitz D. Severe acute pancreatitis as the presenting symptom of primary sclerosing cholangitis: treatment by endoscopic insertion of a biliary stent. Int Surg. 1990;75(1):58-60.
12. Said K, Glaumann H, Bergquist A. Gallbladder disease in patients with primary sclerosing cholangitis. J Hepatol. 2008;48(4):598-605. doi: 10.1016/j.jhep.2007.11.019
13. Srinath AI, Gupta N, Husain SZ. Probing the association of pancreatitis in inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(2):465-75. doi: 10.1097/MIB.0000000000000611
14. Miehsler W, Reinisch W, Valic E, Osterode W, Tillinger W, Feichtenschlager T, et al. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut. 2004;53(4):542-8. doi: 10.1136/gut.2003.025411
15. Zhang FM, Xu CF, Shan GD, Chen HT, Xu GQ. Is gallstone disease associated with inflammatory bowel diseases? A meta-analysis. J Dig Dis. 2015;16(11):634-41. doi: 10.1111/1751-2980.12286
16. Fagagnini S, Heinrich H, Rossel JB, Biedermann L, Frei P, Zeitz J, et al. Risk factors for gallstones and kidney stones in a cohort of patients with inflammatory bowel diseases. PLoS One. 2017;12(10):e0185193. doi: 10.1371/journal.pone.0185193
17. Jeong YH, Kim KO, Lee HC, Sohn SH, Lee JW, Lee SH, et al. Gallstone prevalence and risk factors in patients with ulcerative colitis in Korean population. Medicine (Baltimore). 2017;96(31):e7653. doi: 10.1097/MD.0000000000007653
18. Faintuch J, Mott CB, Machado MC. Pancreatitis and pancreatic necrosis during sulfasalazine therapy. Int Surg. 1985;70(3):271-2.
19. Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions reevaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut. 2002;51(4):536-9. doi: 10.1136/gut.51.4.536
20. Russo L, Schneider G, Gardiner MH, Lanes S, Streck P, Rosen S. Role of pharmacoepidemiology studies in addressing pharmacovigilance questions: a case example of pancreatitis risk among ulcerative colitis patients using mesalazine. Eur J Clin Pharmacol. 2014;70(6):709-17. doi: 10.1007/s00228-014-1660-7
21. Isaacs KL, Murphy D. Pancreatitis after rectal administration of 5-aminosalicylic acid. J Clin Gastroenterol. 1990;12(2):198-9.
22. Stobaugh DJ, Deepak P. Effect of tumor necrosis factor-alpha inhibitors on drug-induced pancreatitis in inflammatory bowel disease. Ann Pharmacother. 2014;48(10):1282-7. doi: 10.1177/1060028014540869
23. Triantafillidis JK, Cheracakis P, Hereti IA, Argyros N, Karra E. Acute idiopathic pancreatitis complicating active Crohn's disease: favorable response to infliximab treatment. Am J Gastroenterol. 2000;95(11):3334-6.
24. Youssef I, Saeed N, El Abdallah M, Huevelhorst K, Zakharia K. Metronidazole-Induced Pancreatitis: Is There Underrecognition? A Case Report and SystematicReview of the Literature. Case Rep Gastrointest Med. 2019;2019:4840539. doi: 10.1155/2019/4840539
25. O'Halloran E, Hogan A, Mealy K. Metronidazole-induced pancreatitis. HPB Surg. 2010;2010:523468. doi: 10.1155/2010/523468
26. Tsesmeli NE, Giannoulis KE, Savopoulos CG, Vretou EE, Ekonomou IA, Giannoulis EK. Acute pancreatitis as a possible consequence of metronidazole during a relapse of ulcerative colitis. Eur J Gastroenterol Hepatol. 2007;19(9):805-6.
27. Sadr-Azodi O, Mattsson F, Bexlius TS, Lindblad M, Lagergren J, Ljung R. Association of oral glucocorticoid use with an increased risk of acute pancreatitis: a population-based nested case-control study. JAMA Int Med. 2013;173(6):444-9. doi: 10.1001/jamainternmed.2013.2737
28. Dong LH, Liu ZM, Wang SJ, Zhao SJ, Zhang D, Chen Y, Wang YS. Corticosteroid therapy for severe acute pancreatitis: a meta-analysis of randomized, controlled trials. Int J Clin Exp Pathol. 2015;8(7):7654-60.
29. Tenner S, Baillie J, DeWitt J, Vege SS, American College of G. American College of Gastroenterology guideline: management of acute pancreatitis. Am J Gastroenterol. 2013;108(9):1400-15;1416. doi: 10.1038/ajg.2013. 218
30. Nesvaderani M, Eslick GD, Cox MR. Acute pancreatitis: update on management. Med J Aust. 2015;202(8):420-3.
31. Okhlobystin AV. Is autoimmune pancreatitis difficult to diagnose? Modern views, treatment approaches and outcomes. Russian medical journal. 2015;21:1281-6 (In Russ.)
32. Tsen A, Alishahi Y, Rosenkranz L. Autoimmune pancreatitis and inflammatory bowel disease: an updated review. J Clin Gastroenterol. 2017;51(3):208-14. doi: 10.1097/MCG.0000000000000737
33. Kamisawa T, Chari ST, Giday SA, Kim MH, Chung JB, Lee KT, et al. Clinical profile of autoimmune pancreatitis and its histological subtypes: an international multicenter survey. Pancreas. 2011;40(6):809-14. doi: 10.1097/MPA.0b013e3182258a15
34. Ueki T, Kawamoto K, Otsuka Y, Minoda R, Maruo T, Matsumura K, et al. Prevalence and clinico-pathological features of autoimmune pancreatitis in Japanese patients with inflammatory bowel disease. Pancreas. 2015;44(3):434-40. doi: 10.1097/MPA.000000000000026
35. Uchida K, Okazaki K. Clinical and pathophysiological aspects of type 1 autoimmune pancreatitis. J Gastroenterol. 2018;53(4):475-83. doi: 10.1007/s00535-018-1440-8
36. Lorenzo D, Maire F, Stefanescu C, Gornet JM, Seksik P, Serrero M, et al. Features of autoimmune pancreatitis associated with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2018;16(1):59-67. doi: 10.1016/j.cgh.2017.07.033
37. Ravi K, Chari ST, Vege SS, Sandborn WJ, Smyrk TC, Loftus EV, Jr. Inflammatory bowel disease in the setting of autoimmune pancreatitis. Inflamm Bowel Dis. 2009;15(9):1326-30. doi: 10.1002/ibd.20898
38. Smyk DS, Rigopoulou EI, Koutsoumpas AL, Kriese S, Burroughs AK, Bogdanos DP. Autoantibodies in autoimmune pancreatitis. Int J Rheumatol. 2012;2012:940831. doi: 10.1155/2012/940831
39. Akhmedov VA, Gaus OV. Modern views on the mechanisms of formation and prospects for the relief of abdominal pain in patients with chronic pancreatitis. Experimental and clinical gastroenterology. 2016;134(10):99-103 (In Russ.)
40. Khatkov IE, Maev IV, Abdulkhakov SR, Alekseenko SA, Alieva EI, Alikhanov RB, et al. Russian consensus on the diagnosis and treatment of chronic pancreatitis. Therapeutic Archive. 2017;89(2):105-13 (In Russ.) doi: 10.17116/ terarkh20178 921 05-113
41. Akhmedov VA, Gaus OV. Damage to the organs of the hepatobiliary system and pancreas in obesity. Therapeutic Archive. 2017;89(1):128-33 (In Russ.) doi: 10.17116/terarkh2017891128-133
42. Rana SS, Vilmann P. Endoscopic ultrasound features of chronic pancreatitis: A pictorial review. Endosc Ultrasound. 2015;4(1):10-4. doi: 10.4103/2303-9027.151314
43. Barthet M, Hastier P, Bernard JP, Bordes G, Frederick J, Allio S, et al. Chronic pancreatitis and inflammatory bowel disease: true or coincidental association? Am J Gastroenterol. 1999;94(8):2141-8.
44. Chen YL, Hsu CW, Cheng CC, Yiang GT, Lin CS, Lin CL, et al. Increased subsequent risk of inflammatory bowel disease association in patients with chronic pancreatitis: a nationwide population-based cohort study. Curr Med Res Opin. 2017;33(6):1077-82. doi: 10.1080/03007995.2017.1300143
45. Khatkov IE, Maev IV, Bordin DS, Kucheryavy YuA, Abdulkhakov SR, Alekseenko SA, et al. Russian consensus on the diagnosis and treatment of chronic pancreatitis: enzyme replacement therapy. Therapeutic Archive. 2017;89(8):80-7 (In Russ.) doi: 10.17116/terarkh 201789880-87
46. Maconi G, Dominici R, Molteni M, Ardizzone S, Bosani M, Ferrara E, et al. Prevalence of pancreatic in sufficiency in inflammatory bowel diseases. Assessment by fecal elastase-1. Dig Dis Sci. 2008;53(1):262-70. doi:10.1007/s10620-007-9852-y
47. Angelini G, Cavallini G, Bovo P, Brocco G, Castagnini A, Lavarini E, et al. Pancreatic function in chronic inflammatory bowel disease. Int J Pancreatol. 1988;3(2-3):185-93.
48. Heikius B, Niemela S, Lehtola J, Karttunen T, Lahde S. Pancreatic duct abnormalities and pancreatic function in patients with chronic inflammatory bowel disease. Scand J Gastroenterol. 1996;31(5):517-23.
49. Soubieres AA, Poullis A. Emerging role of novel bio- markers in the diagnosis of inflammatory bowel disease. World J Gastrointest Pharmacol Ther. 2016;7(1):41-50. doi: 10.4292/ wjgpt.v7.i1.41
50. Bogdanos DP, Rigopoulou EI, Smyk DS, Roggenbuck D, Reinhold D, Forbes A, et al. Diagnostic value, clinical utility and pathogenic significance of reactivity to the molecular targets of Crohn's disease specific-pancreatic autoantibodies. Autoimmun Rev. 2011;11(2):143-8. doi: 10.1016/j.autrev.2011.09.00
51. Bogdanos DP, Roggenbuck D, Reinhold D, Wex T, Pav lidis P, von Arnim U, et al. Pancreatic-specific autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with Crohn's disease. BMC Gastroenterol. 2012;12:102. doi: 10.1186/1471-230X-12-102
52. Pavlidis P, Romanidou O, Roggenbuck D, Mytilinaiou MG, Al-Sulttan F, Liaskos C, et al. Ileal inflammation may trigger the development of GP2-specific pancreatic autoantibodies in patients with Crohn's disease. Clin Dev Immunol. 2012;2012:640835. doi: 10.1155/2012/64083
53. Gross S, Bakker SF, van Bodegraven AA, van Hoogstraten IM, Gelderman KA, Bouma G, et al. Increased IgA glycoprotein-2 specific antibody titres in refractory celiac disease. J Gastrointestin Liver Dis. 2014;23(2):127-33. doi: 10.15403/jgld.2014.1121.232.sg1
54. Tornai T, Tornai D, Sipeki N, Tornai I, Alsulaimani R, Fechner K, Roggenbuck D, et al. Loss of tolerance to gut immunity protein, glycoprotein 2 (GP2) is associated with progressive disease course in primary sclerosing cholangitis. Sci Rep. 2018;8(1):399. doi: 10.1038/s41598-017-18622-1
55. Parfenov AI, Bykova SV, Sabelnikova EA, Mayev IV, Baranov AA, Bakulin IG, et al. All-Russian consensus on the diagnosis and treatment of celiac disease in children and adults. Therapeutic Archive. 2017;89(3):94-107 (In Russ.) doi: 10.17116/terarkh20 1789394-107
56. Fotios S Fousekis, Vasileios I Theopistos, Konstantinos H Katsanos, Dimitrios K Christodoulou. Pancreatic Involvement in Inflammatory Bowel Disease: A Review. J Clin Med Res. 2018;10(10):743-51. doi: 10.14740/jocmr3561w
57. Toda N, Akahane M, Kiryu S, Matsubara Y, Yamaji Y, Okamoto M, et al. Pancreas duct abnormalities in patients with ulcerative colitis: a magnetic resonance pancreatography study. Inflamm Bowel Dis. 2005;11(10):903-8. doi: 10.1097/01.mib.0000183419.17563.17
2. Ramos LR, Sachar DB, DiMaio CJ, Colombel JF, Torres J. Inflammatory bowel disease and pancreatitis: a review. J Crohns Colitis. 2016;10(1):95-104. doi: 10.1093/ecco-jcc/jjv153
3. Spanier BW, Dijkgraaf MG, Bruno MJ. Epidemiology, aetiology and outcome of acute and chronic pancreatitis: an update. Best Pract Res Clin Gastroenterol. 2008;22(1):45-63. doi: 10.1016/j.bpg.2007.10.007
4. Bermejo F, Lopez-Sanroman A, Taxonera C, Gisbert JP, Perez-Calle JL, Vera I, et al. Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine-induced pancreatitis. Aliment Pharmacol Ther. 2008;28(5):623-8. doi: 10.1111/j.1365-2036.2008.03746.x.
5. Weber P, Seibold F, Jenss H. Acute pancreatitis in Crohn's disease. J Clin Gastroenterol. 1993;17(4):286-91.
6. Rasmussen HH, Fonager K, Sorensen HT, Pedersen L, Dahlerup JF, Steffensen FH. Risk of acute pancreatitis in patients with chronic inflammatory bowel disease. A Danish 16-year nationwide follow-up study. Scand J Gastroenterol. 1999;34(2):199-201.
7. Chen YT, Su JS, Tseng CW, Chen CC, Lin CL, Kao CH. Inflammatory bowel disease on the risk of acute pancreatitis: A population-based cohort study. J Gastroenterol Hepatol. 2016;31(4):782-7. doi: 10.1111/ jgh.13171
8. Broide E, Dotan I, Weiss B, Wilschanski M, Yerushalmi B, Klar A, Levine A. Idiopathic pancreatitis preceding the diagnosis of inflammatory bowel disease is more frequent in pediatric patients. J Pediatr Gastroenterol Nutr. 2011;52(6):714-7. doi: 10.1097/MPG. 0b013e3182065cad
9. Moolsintong P, Loftus EV Jr, Chari ST, Egan LJ, Tremaine WJ, Sandborn WJ. Acute pancreatitis in patients with Crohn's disease: clinical features and outcomes. Inflamm Bowel Dis. 2005;11(12):1080-4. doi: 10.1097/01
10. Pajares JA, Hernandez L, Menchen P, Menchen L. Duodenopancreatic fistula complicating upper gastrointestinal Crohn's disease: successful treatment with infliximab. Am J Gastroenterol. 2009;104(7):1863-4. doi: 10.1038/ajg.2009.180
11. Goldin E, Libson E, Wengrower D, Antal S, Kovacs Z, Rachmilewitz D. Severe acute pancreatitis as the presenting symptom of primary sclerosing cholangitis: treatment by endoscopic insertion of a biliary stent. Int Surg. 1990;75(1):58-60.
12. Said K, Glaumann H, Bergquist A. Gallbladder disease in patients with primary sclerosing cholangitis. J Hepatol. 2008;48(4):598-605. doi: 10.1016/j.jhep.2007.11.019
13. Srinath AI, Gupta N, Husain SZ. Probing the association of pancreatitis in inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(2):465-75. doi: 10.1097/MIB.0000000000000611
14. Miehsler W, Reinisch W, Valic E, Osterode W, Tillinger W, Feichtenschlager T, et al. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut. 2004;53(4):542-8. doi: 10.1136/gut.2003.025411
15. Zhang FM, Xu CF, Shan GD, Chen HT, Xu GQ. Is gallstone disease associated with inflammatory bowel diseases? A meta-analysis. J Dig Dis. 2015;16(11):634-41. doi: 10.1111/1751-2980.12286
16. Fagagnini S, Heinrich H, Rossel JB, Biedermann L, Frei P, Zeitz J, et al. Risk factors for gallstones and kidney stones in a cohort of patients with inflammatory bowel diseases. PLoS One. 2017;12(10):e0185193. doi: 10.1371/journal.pone.0185193
17. Jeong YH, Kim KO, Lee HC, Sohn SH, Lee JW, Lee SH, et al. Gallstone prevalence and risk factors in patients with ulcerative colitis in Korean population. Medicine (Baltimore). 2017;96(31):e7653. doi: 10.1097/MD.0000000000007653
18. Faintuch J, Mott CB, Machado MC. Pancreatitis and pancreatic necrosis during sulfasalazine therapy. Int Surg. 1985;70(3):271-2.
19. Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions reevaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut. 2002;51(4):536-9. doi: 10.1136/gut.51.4.536
20. Russo L, Schneider G, Gardiner MH, Lanes S, Streck P, Rosen S. Role of pharmacoepidemiology studies in addressing pharmacovigilance questions: a case example of pancreatitis risk among ulcerative colitis patients using mesalazine. Eur J Clin Pharmacol. 2014;70(6):709-17. doi: 10.1007/s00228-014-1660-7
21. Isaacs KL, Murphy D. Pancreatitis after rectal administration of 5-aminosalicylic acid. J Clin Gastroenterol. 1990;12(2):198-9.
22. Stobaugh DJ, Deepak P. Effect of tumor necrosis factor-alpha inhibitors on drug-induced pancreatitis in inflammatory bowel disease. Ann Pharmacother. 2014;48(10):1282-7. doi: 10.1177/1060028014540869
23. Triantafillidis JK, Cheracakis P, Hereti IA, Argyros N, Karra E. Acute idiopathic pancreatitis complicating active Crohn's disease: favorable response to infliximab treatment. Am J Gastroenterol. 2000;95(11):3334-6.
24. Youssef I, Saeed N, El Abdallah M, Huevelhorst K, Zakharia K. Metronidazole-Induced Pancreatitis: Is There Underrecognition? A Case Report and SystematicReview of the Literature. Case Rep Gastrointest Med. 2019;2019:4840539. doi: 10.1155/2019/4840539
25. O'Halloran E, Hogan A, Mealy K. Metronidazole-induced pancreatitis. HPB Surg. 2010;2010:523468. doi: 10.1155/2010/523468
26. Tsesmeli NE, Giannoulis KE, Savopoulos CG, Vretou EE, Ekonomou IA, Giannoulis EK. Acute pancreatitis as a possible consequence of metronidazole during a relapse of ulcerative colitis. Eur J Gastroenterol Hepatol. 2007;19(9):805-6.
27. Sadr-Azodi O, Mattsson F, Bexlius TS, Lindblad M, Lagergren J, Ljung R. Association of oral glucocorticoid use with an increased risk of acute pancreatitis: a population-based nested case-control study. JAMA Int Med. 2013;173(6):444-9. doi: 10.1001/jamainternmed.2013.2737
28. Dong LH, Liu ZM, Wang SJ, Zhao SJ, Zhang D, Chen Y, Wang YS. Corticosteroid therapy for severe acute pancreatitis: a meta-analysis of randomized, controlled trials. Int J Clin Exp Pathol. 2015;8(7):7654-60.
29. Tenner S, Baillie J, DeWitt J, Vege SS, American College of G. American College of Gastroenterology guideline: management of acute pancreatitis. Am J Gastroenterol. 2013;108(9):1400-15;1416. doi: 10.1038/ajg.2013. 218
30. Nesvaderani M, Eslick GD, Cox MR. Acute pancreatitis: update on management. Med J Aust. 2015;202(8):420-3.
31. Охлобыстин А.В. Трудно ли диагностировать аутоиммунный панкреатит? Современные представления, подходы к лечению и исходы. Русский медицинский журнал. 2015;21:1281-6 [Okhlobystin AV. Is autoimmune pancreatitis difficult to diagnose? Modern views, treatment approaches and outcomes. Russian medical journal. 2015;21:1281-6 (In Russ.)].
32. Tsen A, Alishahi Y, Rosenkranz L. Autoimmune pancreatitis and inflammatory bowel disease: an updated review. J Clin Gastroenterol. 2017;51(3):208-14. doi: 10.1097/MCG.0000000000000737
33. Kamisawa T, Chari ST, Giday SA, Kim MH, Chung JB, Lee KT, et al. Clinical profile of autoimmune pancreatitis and its histological subtypes: an international multicenter survey. Pancreas. 2011;40(6):809-14. doi: 10.1097/MPA.0b013e3182258a15
34. Ueki T, Kawamoto K, Otsuka Y, Minoda R, Maruo T, Matsumura K, et al. Prevalence and clinico-pathological features of autoimmune pancreatitis in Japanese patients with inflammatory bowel disease. Pancreas. 2015;44(3):434-40. doi: 10.1097/MPA.000000000000026
35. Uchida K, Okazaki K. Clinical and pathophysiological aspects of type 1 autoimmune pancreatitis. J Gastroenterol. 2018;53(4):475-83. doi: 10.1007/s00535-018-1440-8
36. Lorenzo D, Maire F, Stefanescu C, Gornet JM, Seksik P, Serrero M, et al. Features of autoimmune pancreatitis associated with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2018;16(1):59-67. doi: 10.1016/j.cgh.2017.07.033
37. Ravi K, Chari ST, Vege SS, Sandborn WJ, Smyrk TC, Loftus EV, Jr. Inflammatory bowel disease in the setting of autoimmune pancreatitis. Inflamm Bowel Dis. 2009;15(9):1326-30. doi: 10.1002/ibd.20898
38. Smyk DS, Rigopoulou EI, Koutsoumpas AL, Kriese S, Burroughs AK, Bogdanos DP. Autoantibodies in autoimmune pancreatitis. Int J Rheumatol. 2012;2012:940831. doi: 10.1155/2012/940831
39. Ахмедов В.А., Гаус О.В. Современные взгляды на механизмы формирования и перспективы купирования болевого абдоминального синдрома у пациентов хроническим панкреатитом. Экспериментальная и клиническая гастроэнтерология. 2016;134(10):99-103 [Akhmedov VA, Gaus OV. Modern views on the mechanisms of formation and prospects for the relief of abdominal pain in patients with chronic pancreatitis. Experimental and clinical gastroenterology. 2016;134(10):99-103 (In Russ.)].
40. Хатьков И.Е., Маев И.В., Абдулхаков С.Р., Алексеенко С.А., Алиева Э.И., Алиханов Р.Б. и др. Российский консенсус по диагностике и лечению хронического панкреатита. Терапевтический архив. 2017;89(2):105-13 [Khatkov IE, Maev IV, Abdulkhakov SR, Alekseenko SA, Alieva EI, Alikhanov RB, et al. Russian consensus on the diagnosis and treatment of chronic pancreatitis. Therapeutic Archive. 2017;89(2):105-13 (In Russ.)]. doi: 10.17116/ terarkh20178 921 05-113
41. Ахмедов В.А., Гаус О.В. Поражение органов гепатобилиарной системы и поджелудочной железы при ожирении. Терапевтический архив. 2017;89(1):128-33 [Akhmedov VA, Gaus OV. Damage to the organs of the hepatobiliary system and pancreas in obesity. Therapeutic Archive. 2017;89(1):128-33 (In Russ.)]. doi: 10.17116/terarkh2017891128-133
42. Rana SS, Vilmann P. Endoscopic ultrasound features of chronic pancreatitis: A pictorial review. Endosc Ultrasound. 2015;4(1):10-4. doi: 10.4103/2303-9027.151314
43. Barthet M, Hastier P, Bernard JP, Bordes G, Frederick J, Allio S, et al. Chronic pancreatitis and inflammatory bowel disease: true or coincidental association? Am J Gastroenterol. 1999;94(8):2141-8.
44. Chen YL, Hsu CW, Cheng CC, Yiang GT, Lin CS, Lin CL, et al. Increased subsequent risk of inflammatory bowel disease association in patients with chronic pancreatitis: a nationwide population-based cohort study. Curr Med Res Opin. 2017;33(6):1077-82. doi: 10.1080/03007995.2017.1300143
45. Хатьков И.Е., Маев И.В., Бордин Д.С., Кучерявый Ю.А., Абдулхаков С.Р., Алексеенко С.А. и др. Российский консенсус по диагностике и лечению хронического панкреатита: заместительная ферментная терапия. Терапевтический архив. 2017;89(8):80-7 [Khatkov IE, Maev IV, Bordin DS, Kucheryavy YuA, Abdulkhakov SR, Alekseenko SA, et al. Russian consensus on the diagnosis and treatment of chronic pancreatitis: enzyme replacement therapy. Therapeutic Archive. 2017;89(8):80-7 (In Russ.)]. doi: 10.17116/terarkh 201789880-87
46. Maconi G, Dominici R, Molteni M, Ardizzone S, Bosani M, Ferrara E, et al. Prevalence of pancreatic in sufficiency in inflammatory bowel diseases. Assessment by fecal elastase-1. Dig Dis Sci. 2008;53(1):262-70. doi:10.1007/s10620-007-9852-y
47. Angelini G, Cavallini G, Bovo P, Brocco G, Castagnini A, Lavarini E, et al. Pancreatic function in chronic inflammatory bowel disease. Int J Pancreatol. 1988;3(2-3):185-93.
48. Heikius B, Niemela S, Lehtola J, Karttunen T, Lahde S. Pancreatic duct abnormalities and pancreatic function in patients with chronic inflammatory bowel disease. Scand J Gastroenterol. 1996;31(5):517-23.
49. Soubieres AA, Poullis A. Emerging role of novel bio- markers in the diagnosis of inflammatory bowel disease. World J Gastrointest Pharmacol Ther. 2016;7(1):41-50. doi: 10.4292/ wjgpt.v7.i1.41
50. Bogdanos DP, Rigopoulou EI, Smyk DS, Roggenbuck D, Reinhold D, Forbes A, et al. Diagnostic value, clinical utility and pathogenic significance of reactivity to the molecular targets of Crohn's disease specific-pancreatic autoantibodies. Autoimmun Rev. 2011;11(2):143-8. doi: 10.1016/j.autrev.2011.09.00
51. Bogdanos DP, Roggenbuck D, Reinhold D, Wex T, Pav lidis P, von Arnim U, et al. Pancreatic-specific autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with Crohn's disease. BMC Gastroenterol. 2012;12:102. doi: 10.1186/1471-230X-12-102
52. Pavlidis P, Romanidou O, Roggenbuck D, Mytilinaiou MG, Al-Sulttan F, Liaskos C, et al. Ileal inflammation may trigger the development of GP2-specific pancreatic autoantibodies in patients with Crohn's disease. Clin Dev Immunol. 2012;2012:640835. doi: 10.1155/2012/64083
53. Gross S, Bakker SF, van Bodegraven AA, van Hoogstraten IM, Gelderman KA, Bouma G, et al. Increased IgA glycoprotein-2 specific antibody titres in refractory celiac disease. J Gastrointestin Liver Dis. 2014;23(2):127-33. doi: 10.15403/jgld.2014.1121.232.sg1
54. Tornai T, Tornai D, Sipeki N, Tornai I, Alsulaimani R, Fechner K, Roggenbuck D, et al. Loss of tolerance to gut immunity protein, glycoprotein 2 (GP2) is associated with progressive disease course in primary sclerosing cholangitis. Sci Rep. 2018;8(1):399. doi: 10.1038/s41598-017-18622-1
55. Парфенов А.И., Быкова С.В., Сабельникова Е.А., Маев И.В., Баранов А.А., Бакулин И.Г. и др. Всероссийский консенсус по диагностике и лечению целиакии у детей и взрослых. Терапевтический архив. 2017;89(3):94-107 [Parfenov AI, Bykova SV, Sabelnikova EA, Mayev IV, Baranov AA, Bakulin IG, et al. All-Russian consensus on the diagnosis and treatment of celiac disease in children and adults. Therapeutic Archive. 2017;89(3):94-107 (In Russ.)]. doi: 10.17116/terarkh20 1789394-107
56. Fotios S Fousekis, Vasileios I Theopistos, Konstantinos H Katsanos, Dimitrios K Christodoulou. Pancreatic Involvement in Inflammatory Bowel Disease: A Review. J Clin Med Res. 2018;10(10):743-51. doi: 10.14740/jocmr3561w
57. Toda N, Akahane M, Kiryu S, Matsubara Y, Yamaji Y, Okamoto M, et al. Pancreas duct abnormalities in patients with ulcerative colitis: a magnetic resonance pancreatography study. Inflamm Bowel Dis. 2005;11(10):903-8. doi: 10.1097/01.mib.0000183419.17563.17
________________________________________________
2. Ramos LR, Sachar DB, DiMaio CJ, Colombel JF, Torres J. Inflammatory bowel disease and pancreatitis: a review. J Crohns Colitis. 2016;10(1):95-104. doi: 10.1093/ecco-jcc/jjv153
3. Spanier BW, Dijkgraaf MG, Bruno MJ. Epidemiology, aetiology and outcome of acute and chronic pancreatitis: an update. Best Pract Res Clin Gastroenterol. 2008;22(1):45-63. doi: 10.1016/j.bpg.2007.10.007
4. Bermejo F, Lopez-Sanroman A, Taxonera C, Gisbert JP, Perez-Calle JL, Vera I, et al. Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine-induced pancreatitis. Aliment Pharmacol Ther. 2008;28(5):623-8. doi: 10.1111/j.1365-2036.2008.03746.x.
5. Weber P, Seibold F, Jenss H. Acute pancreatitis in Crohn's disease. J Clin Gastroenterol. 1993;17(4):286-91.
6. Rasmussen HH, Fonager K, Sorensen HT, Pedersen L, Dahlerup JF, Steffensen FH. Risk of acute pancreatitis in patients with chronic inflammatory bowel disease. A Danish 16-year nationwide follow-up study. Scand J Gastroenterol. 1999;34(2):199-201.
7. Chen YT, Su JS, Tseng CW, Chen CC, Lin CL, Kao CH. Inflammatory bowel disease on the risk of acute pancreatitis: A population-based cohort study. J Gastroenterol Hepatol. 2016;31(4):782-7. doi: 10.1111/ jgh.13171
8. Broide E, Dotan I, Weiss B, Wilschanski M, Yerushalmi B, Klar A, Levine A. Idiopathic pancreatitis preceding the diagnosis of inflammatory bowel disease is more frequent in pediatric patients. J Pediatr Gastroenterol Nutr. 2011;52(6):714-7. doi: 10.1097/MPG. 0b013e3182065cad
9. Moolsintong P, Loftus EV Jr, Chari ST, Egan LJ, Tremaine WJ, Sandborn WJ. Acute pancreatitis in patients with Crohn's disease: clinical features and outcomes. Inflamm Bowel Dis. 2005;11(12):1080-4. doi: 10.1097/01
10. Pajares JA, Hernandez L, Menchen P, Menchen L. Duodenopancreatic fistula complicating upper gastrointestinal Crohn's disease: successful treatment with infliximab. Am J Gastroenterol. 2009;104(7):1863-4. doi: 10.1038/ajg.2009.180
11. Goldin E, Libson E, Wengrower D, Antal S, Kovacs Z, Rachmilewitz D. Severe acute pancreatitis as the presenting symptom of primary sclerosing cholangitis: treatment by endoscopic insertion of a biliary stent. Int Surg. 1990;75(1):58-60.
12. Said K, Glaumann H, Bergquist A. Gallbladder disease in patients with primary sclerosing cholangitis. J Hepatol. 2008;48(4):598-605. doi: 10.1016/j.jhep.2007.11.019
13. Srinath AI, Gupta N, Husain SZ. Probing the association of pancreatitis in inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(2):465-75. doi: 10.1097/MIB.0000000000000611
14. Miehsler W, Reinisch W, Valic E, Osterode W, Tillinger W, Feichtenschlager T, et al. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut. 2004;53(4):542-8. doi: 10.1136/gut.2003.025411
15. Zhang FM, Xu CF, Shan GD, Chen HT, Xu GQ. Is gallstone disease associated with inflammatory bowel diseases? A meta-analysis. J Dig Dis. 2015;16(11):634-41. doi: 10.1111/1751-2980.12286
16. Fagagnini S, Heinrich H, Rossel JB, Biedermann L, Frei P, Zeitz J, et al. Risk factors for gallstones and kidney stones in a cohort of patients with inflammatory bowel diseases. PLoS One. 2017;12(10):e0185193. doi: 10.1371/journal.pone.0185193
17. Jeong YH, Kim KO, Lee HC, Sohn SH, Lee JW, Lee SH, et al. Gallstone prevalence and risk factors in patients with ulcerative colitis in Korean population. Medicine (Baltimore). 2017;96(31):e7653. doi: 10.1097/MD.0000000000007653
18. Faintuch J, Mott CB, Machado MC. Pancreatitis and pancreatic necrosis during sulfasalazine therapy. Int Surg. 1985;70(3):271-2.
19. Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions reevaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut. 2002;51(4):536-9. doi: 10.1136/gut.51.4.536
20. Russo L, Schneider G, Gardiner MH, Lanes S, Streck P, Rosen S. Role of pharmacoepidemiology studies in addressing pharmacovigilance questions: a case example of pancreatitis risk among ulcerative colitis patients using mesalazine. Eur J Clin Pharmacol. 2014;70(6):709-17. doi: 10.1007/s00228-014-1660-7
21. Isaacs KL, Murphy D. Pancreatitis after rectal administration of 5-aminosalicylic acid. J Clin Gastroenterol. 1990;12(2):198-9.
22. Stobaugh DJ, Deepak P. Effect of tumor necrosis factor-alpha inhibitors on drug-induced pancreatitis in inflammatory bowel disease. Ann Pharmacother. 2014;48(10):1282-7. doi: 10.1177/1060028014540869
23. Triantafillidis JK, Cheracakis P, Hereti IA, Argyros N, Karra E. Acute idiopathic pancreatitis complicating active Crohn's disease: favorable response to infliximab treatment. Am J Gastroenterol. 2000;95(11):3334-6.
24. Youssef I, Saeed N, El Abdallah M, Huevelhorst K, Zakharia K. Metronidazole-Induced Pancreatitis: Is There Underrecognition? A Case Report and SystematicReview of the Literature. Case Rep Gastrointest Med. 2019;2019:4840539. doi: 10.1155/2019/4840539
25. O'Halloran E, Hogan A, Mealy K. Metronidazole-induced pancreatitis. HPB Surg. 2010;2010:523468. doi: 10.1155/2010/523468
26. Tsesmeli NE, Giannoulis KE, Savopoulos CG, Vretou EE, Ekonomou IA, Giannoulis EK. Acute pancreatitis as a possible consequence of metronidazole during a relapse of ulcerative colitis. Eur J Gastroenterol Hepatol. 2007;19(9):805-6.
27. Sadr-Azodi O, Mattsson F, Bexlius TS, Lindblad M, Lagergren J, Ljung R. Association of oral glucocorticoid use with an increased risk of acute pancreatitis: a population-based nested case-control study. JAMA Int Med. 2013;173(6):444-9. doi: 10.1001/jamainternmed.2013.2737
28. Dong LH, Liu ZM, Wang SJ, Zhao SJ, Zhang D, Chen Y, Wang YS. Corticosteroid therapy for severe acute pancreatitis: a meta-analysis of randomized, controlled trials. Int J Clin Exp Pathol. 2015;8(7):7654-60.
29. Tenner S, Baillie J, DeWitt J, Vege SS, American College of G. American College of Gastroenterology guideline: management of acute pancreatitis. Am J Gastroenterol. 2013;108(9):1400-15;1416. doi: 10.1038/ajg.2013. 218
30. Nesvaderani M, Eslick GD, Cox MR. Acute pancreatitis: update on management. Med J Aust. 2015;202(8):420-3.
31. Okhlobystin AV. Is autoimmune pancreatitis difficult to diagnose? Modern views, treatment approaches and outcomes. Russian medical journal. 2015;21:1281-6 (In Russ.)
32. Tsen A, Alishahi Y, Rosenkranz L. Autoimmune pancreatitis and inflammatory bowel disease: an updated review. J Clin Gastroenterol. 2017;51(3):208-14. doi: 10.1097/MCG.0000000000000737
33. Kamisawa T, Chari ST, Giday SA, Kim MH, Chung JB, Lee KT, et al. Clinical profile of autoimmune pancreatitis and its histological subtypes: an international multicenter survey. Pancreas. 2011;40(6):809-14. doi: 10.1097/MPA.0b013e3182258a15
34. Ueki T, Kawamoto K, Otsuka Y, Minoda R, Maruo T, Matsumura K, et al. Prevalence and clinico-pathological features of autoimmune pancreatitis in Japanese patients with inflammatory bowel disease. Pancreas. 2015;44(3):434-40. doi: 10.1097/MPA.000000000000026
35. Uchida K, Okazaki K. Clinical and pathophysiological aspects of type 1 autoimmune pancreatitis. J Gastroenterol. 2018;53(4):475-83. doi: 10.1007/s00535-018-1440-8
36. Lorenzo D, Maire F, Stefanescu C, Gornet JM, Seksik P, Serrero M, et al. Features of autoimmune pancreatitis associated with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2018;16(1):59-67. doi: 10.1016/j.cgh.2017.07.033
37. Ravi K, Chari ST, Vege SS, Sandborn WJ, Smyrk TC, Loftus EV, Jr. Inflammatory bowel disease in the setting of autoimmune pancreatitis. Inflamm Bowel Dis. 2009;15(9):1326-30. doi: 10.1002/ibd.20898
38. Smyk DS, Rigopoulou EI, Koutsoumpas AL, Kriese S, Burroughs AK, Bogdanos DP. Autoantibodies in autoimmune pancreatitis. Int J Rheumatol. 2012;2012:940831. doi: 10.1155/2012/940831
39. Akhmedov VA, Gaus OV. Modern views on the mechanisms of formation and prospects for the relief of abdominal pain in patients with chronic pancreatitis. Experimental and clinical gastroenterology. 2016;134(10):99-103 (In Russ.)
40. Khatkov IE, Maev IV, Abdulkhakov SR, Alekseenko SA, Alieva EI, Alikhanov RB, et al. Russian consensus on the diagnosis and treatment of chronic pancreatitis. Therapeutic Archive. 2017;89(2):105-13 (In Russ.) doi: 10.17116/ terarkh20178 921 05-113
41. Akhmedov VA, Gaus OV. Damage to the organs of the hepatobiliary system and pancreas in obesity. Therapeutic Archive. 2017;89(1):128-33 (In Russ.) doi: 10.17116/terarkh2017891128-133
42. Rana SS, Vilmann P. Endoscopic ultrasound features of chronic pancreatitis: A pictorial review. Endosc Ultrasound. 2015;4(1):10-4. doi: 10.4103/2303-9027.151314
43. Barthet M, Hastier P, Bernard JP, Bordes G, Frederick J, Allio S, et al. Chronic pancreatitis and inflammatory bowel disease: true or coincidental association? Am J Gastroenterol. 1999;94(8):2141-8.
44. Chen YL, Hsu CW, Cheng CC, Yiang GT, Lin CS, Lin CL, et al. Increased subsequent risk of inflammatory bowel disease association in patients with chronic pancreatitis: a nationwide population-based cohort study. Curr Med Res Opin. 2017;33(6):1077-82. doi: 10.1080/03007995.2017.1300143
45. Khatkov IE, Maev IV, Bordin DS, Kucheryavy YuA, Abdulkhakov SR, Alekseenko SA, et al. Russian consensus on the diagnosis and treatment of chronic pancreatitis: enzyme replacement therapy. Therapeutic Archive. 2017;89(8):80-7 (In Russ.) doi: 10.17116/terarkh 201789880-87
46. Maconi G, Dominici R, Molteni M, Ardizzone S, Bosani M, Ferrara E, et al. Prevalence of pancreatic in sufficiency in inflammatory bowel diseases. Assessment by fecal elastase-1. Dig Dis Sci. 2008;53(1):262-70. doi:10.1007/s10620-007-9852-y
47. Angelini G, Cavallini G, Bovo P, Brocco G, Castagnini A, Lavarini E, et al. Pancreatic function in chronic inflammatory bowel disease. Int J Pancreatol. 1988;3(2-3):185-93.
48. Heikius B, Niemela S, Lehtola J, Karttunen T, Lahde S. Pancreatic duct abnormalities and pancreatic function in patients with chronic inflammatory bowel disease. Scand J Gastroenterol. 1996;31(5):517-23.
49. Soubieres AA, Poullis A. Emerging role of novel bio- markers in the diagnosis of inflammatory bowel disease. World J Gastrointest Pharmacol Ther. 2016;7(1):41-50. doi: 10.4292/ wjgpt.v7.i1.41
50. Bogdanos DP, Rigopoulou EI, Smyk DS, Roggenbuck D, Reinhold D, Forbes A, et al. Diagnostic value, clinical utility and pathogenic significance of reactivity to the molecular targets of Crohn's disease specific-pancreatic autoantibodies. Autoimmun Rev. 2011;11(2):143-8. doi: 10.1016/j.autrev.2011.09.00
51. Bogdanos DP, Roggenbuck D, Reinhold D, Wex T, Pav lidis P, von Arnim U, et al. Pancreatic-specific autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with Crohn's disease. BMC Gastroenterol. 2012;12:102. doi: 10.1186/1471-230X-12-102
52. Pavlidis P, Romanidou O, Roggenbuck D, Mytilinaiou MG, Al-Sulttan F, Liaskos C, et al. Ileal inflammation may trigger the development of GP2-specific pancreatic autoantibodies in patients with Crohn's disease. Clin Dev Immunol. 2012;2012:640835. doi: 10.1155/2012/64083
53. Gross S, Bakker SF, van Bodegraven AA, van Hoogstraten IM, Gelderman KA, Bouma G, et al. Increased IgA glycoprotein-2 specific antibody titres in refractory celiac disease. J Gastrointestin Liver Dis. 2014;23(2):127-33. doi: 10.15403/jgld.2014.1121.232.sg1
54. Tornai T, Tornai D, Sipeki N, Tornai I, Alsulaimani R, Fechner K, Roggenbuck D, et al. Loss of tolerance to gut immunity protein, glycoprotein 2 (GP2) is associated with progressive disease course in primary sclerosing cholangitis. Sci Rep. 2018;8(1):399. doi: 10.1038/s41598-017-18622-1
55. Parfenov AI, Bykova SV, Sabelnikova EA, Mayev IV, Baranov AA, Bakulin IG, et al. All-Russian consensus on the diagnosis and treatment of celiac disease in children and adults. Therapeutic Archive. 2017;89(3):94-107 (In Russ.) doi: 10.17116/terarkh20 1789394-107
56. Fotios S Fousekis, Vasileios I Theopistos, Konstantinos H Katsanos, Dimitrios K Christodoulou. Pancreatic Involvement in Inflammatory Bowel Disease: A Review. J Clin Med Res. 2018;10(10):743-51. doi: 10.14740/jocmr3561w
57. Toda N, Akahane M, Kiryu S, Matsubara Y, Yamaji Y, Okamoto M, et al. Pancreas duct abnormalities in patients with ulcerative colitis: a magnetic resonance pancreatography study. Inflamm Bowel Dis. 2005;11(10):903-8. doi: 10.1097/01.mib.0000183419.17563.17
Авторы
В.А. Ахмедов, О.В. Гаус
ФГБОУ ВО «Омский государственный медицинский университет» Минздрава России, Омск, Россия
Omsk State Medical University, Omsk, Russia
ФГБОУ ВО «Омский государственный медицинский университет» Минздрава России, Омск, Россия
________________________________________________
Omsk State Medical University, Omsk, Russia
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.